Founder and CEO, Dr. Sandi Dunn, presented insights from Phoenix Molecular Designs’ late-breaking poster presentation. Delving into the PMD-026 Phase I/Ib study, she discussed how patient selection for high RSK2 expression could be pivotal for achieving enhanced Progression-Free Survival (PFS) in metastatic breast cancer. Find a link to the poster here: Patient Selection for High RSK2 Expression is Key for Achieving Improved PFS in Metastatic Breast Cancer in the PMD-026 Phase I/Ib Study